MK-1925 

MK-1925 (compound 39) is a ORL1 receptor antagonist with human IC₅₀ values of 8.2 nM and 4.6 nM, as well as oral bioavailability and blood-brain barrier penetration. MK-1925 selectively inhibits the ORL1 receptor and shows no significant activity against other opioid receptors or the hERG potassium channel^[1].

MK-1925 (compound 39) is highly selective for ORL1 receptors over human μ, κ, and δ opioid receptors, with ORL1 binding IC₅₀ of 8.2 nM and minimal binding to other opioid receptors (IC₅₀ values ≥9800 nM or >10,000 nM)^[1].
MK-1925 has minimal binding affinity for hERG potassium channels, with an IC₅₀ of 9500 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

362.40

C₁₉H₂₁F₃N₄

932705-04-9

C(CC#N)N1C(=C(C)C(CN[C@@H]2C[C@H](F)CC2)=N1)C3=CC(F)=CC(F)=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kobayashi K, et al. Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009;19(16):4729-4732.  [Content Brief]